A Study of LY3502970 in Participants With Obesity or Overweight With Weight-related Comorbidities
Part of paid clinical trials in Anaheim, California.
- Sponsor
- Eli Lilly and Company
- Study ID
- NCT05051579
- Phase
- PHASE2
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 75 Years
- Healthy Volunteers
- Not accepted
Interventions
- LY3502970 — DRUGAdministered orally
- Placebo — DRUGAdministered orally
Study Details
The main purpose of the study was to assess the effect of LY3502970 in participants who have obesity or are overweight.
Key Dates
- Start date
- Sep 29, 2021
- Status verified
- Aug 2023
- Primary completion
- Aug 25, 2022
- Completion
- Nov 22, 2022
Study Design
- Enrollment
- 272 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: 12 milligram (mg) LY3502970Participants received maintenance dose 12 mg with dose escalation starting from 3 mg,6 mg and then 12 mg LY3502970 administered orally once daily until 36 weeks.
- Experimental: 24 mg LY3502970Participants received maintenance dose 24 mg with dose escalation starting from 3 mg, 6 mg, 8 mg,12 mg and then 24 mg LY3502970 administered orally once daily until 36 weeks.
- Experimental: 36 mg-1 LY3502970Participants received maintenance dose 36 mg with dose escalation starting from 2 mg, 3 mg, 6 mg, 8 mg, 12 mg, 24 mg and then 36 mg LY3502970 administered orally once daily until 36 weeks.
- Experimental: 36 mg-2 LY3502970Participants received maintenance dose 36 mg with dose escalation starting from 3 mg, 6 mg,12 mg, 24 mg and then 36 mg LY3502970 administered orally once daily until 36 weeks.
- Experimental: 45 mg-1 LY3502970Participants received maintenance dose 45 mg with dose escalation starting from 3 mg, 6 mg, 8 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 administered orally once daily until 36 weeks.
- Experimental: 45 mg-2 LY3502970Participants received maintenance dose 45 mg with dose escalation starting from 2 mg, 3 mg, 6 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 administered orally once daily until 36 weeks.
- Placebo Comparator: PlaceboParticipants received placebo administered orally once daily until 36 weeks.
Primary Outcome Measure
Percent Change From Baseline in Body Weight in LY3502970 and Placebo [ Time Frame: Baseline, Week 26 ]
Locations (18)
Find similar trials in Anaheim, CA
By condition
By specialty
Related Studies
- Bariatric Embolization of Arteries for the Treatment of Nonalcoholic SteatohepatitisNot Yet Recruiting · Keith Pereira, MD: · St Louis, Missouri
- Inflammation, Diabetes, Ethnicity and Obesity CohortRecruiting · University of California, San Francisco · San Francisco, California
- Differences in Sitting Versus Standing on Metabolic and Cardiovascular MeasurementsEnrolling By Invitation · Montclair State University · Montclair, New Jersey
- Improving Glycemic Control With Electrical StimulationRecruiting · University of Texas, El Paso · El Paso, Texas